Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma 9-04-2024, 13:00

King Faisal Specialist Hospital and Research Centre Showcases its Health Innovations and Solutions at the Global Health Exhibition 28-10-2023, 16:00